About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of Action
PRANLUKAST (ID 27199) exhibits a complex, multi‑pathway biochemical activity profile influencing enzymatic cascades, receptor‑mediated signalling networks, mitochondrial respiration, oxidative‑stress balance, intracellular ion regulation, membrane‑potential stability and transcription‑factor activation. Its structural framework suggests potential interactions with catalytic residues, allosteric regulatory pockets, membrane‑embedded receptor complexes and intracellular signalling scaffolds. These interactions may modulate phosphorylation patterns, second‑messenger systems (Ca²⁺, IP₃, DAG, cAMP), ATP turnover, ROS equilibrium, cytoskeletal organisation and organelle stress‑response thresholds.
Depending on dosing, PRANLUKAST can influence metabolic flux routing, alter chromatin accessibility, modify vesicular transport, reshape mitochondrial output and regulate transcriptional clusters associated with cellular survival, apoptosis, autophagy, inflammatory signalling and metabolic adaptation. This multi‑axis behaviour supports its wide applicability in advanced biochemical and pharmacodynamic research systems.
Benefits and Advantages
The compound is widely utilised for:
- Receptor–ligand interaction analysis and affinity modelling
- Enzyme‑kinetic profiling and catalytic‑pathway reconstruction
- Mitochondrial‑bioenergetics assays and oxidative‑stress evaluation
- Multi‑omics integration (transcriptomics, proteomics, metabolomics, phosphoproteomics)
- Cytoskeletal and membrane‑dynamics studies
- Apoptosis, necroptosis, autophagy and ferroptosis pathway characterisation
- SAR (structure–activity relationship) development and molecular screening
- Pharmacodynamic modelling and mechanistic dose–response simulations
Side Effects and Risks
Potential laboratory‑observed risks include:
- Excessive ROS production and oxidative imbalance
- Mitochondrial hyperactivation or suppression of electron‑transport complexes
- Ion‑channel dysregulation (Na⁺, K⁺, Ca²⁺)
- Unintended receptor cross‑talk or inhibition
- Cytoskeletal destabilisation and membrane‑integrity compromise
- Dose‑dependent cytotoxicity or activation of apoptotic/autophagic pathways
- Transcriptional or epigenetic instability
- Upregulation of inflammatory cascades (NF‑κB, JNK, p38 MAPK)
Use exclusively within controlled laboratory conditions and according to strict biosafety standards.
Datasheet
| Molecular Formula | C27H23FN2O4S |
|---|---|
| Molecular Weight | 481.5 g/mol |
| CAS Number | 103177-37-3 |
| Storage Condition | Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light. |
| Solubility | Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance. |
| Purity | Purity information is available upon request (COA). |
| Synonym | Pranlukast; 103177-37-3; Azlaire; Ono-1078; ONO 1078 |
| IUPAC/Chemical Name | N-[4-oxo-2-(2H-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide |
| InChl Key | NBQKINXMPLXUET-UHFFFAOYSA-N |
| InChl Code | InChI=1S/C27H23N5O4/c33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18/h1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32) |
| References |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.
